Table 4. Complications and morbidities associated with progestational therapy.

Variables		MA group (n=74)	LNG-IUS group (n=74)	p-value
Hysterectomy (due to persistence/progression)		15 (20.3)	6 (8.1)	0.033*
Post-hysterectomy histopathological result
	Normal	1	0
	Atypical hyperplasia	15	5
	Endometrial carcinoma	0	1
Weight after 12 months		96.9±8.3	93.8±5.5	0.009*
Weight after 24 months		100±8.7	95.2±5.1	<0.001*
Weight gain after 12 months		4.7±4	2.7±2.6	0.001*
Weight gain after 24 months		7.8±5.1	4.1±2.9	<0.001*
Glycemic control at 3 months of therapy				0.003*	Post-hoc
	Normal	43 (58.1)	53 (71.6)
	Controlled pretherapy diabetes	6 (8.1)	15 (20.3)		0.15
	Poorly controlled pretherapy diabetes	8 (10.8)	2 (2.7)		0.32
	New onset glucose intolerance	11 (14.9)	2 (2.7)		0.03*
	New-onset diabetes mellitus	3 (4.1)	0 (0.0)		0.31
Glycemic control at 12 months of therapy				0.006*	Post-hoc
	Normal	40 (54.1)	50 (67.6)
	Controlled pretherapy diabetes	7 (9.5)	15 (20.3)		0.28
	Poorly controlled pretherapy diabetes	7 (9.5)	2 (2.7)		0.33
	New onset glucose intolerance	9 (12.2)	5 (6.8)		0.25
	New-onset diabetes mellitus	8 (10.8)	0 (0.0)		0.01*
Blood pressure at 6 months of therapy				0.030*	Post-hoc
	Normal	58 (78.4)	63 (85.1)
	Controlled pretherapy hypertension	3 (4.1)	8 (10.8)		0.36
	Poorly controlled pretherapy hypertension	3 (4.1)	1 (1.4)		0.91
	New onset hypertension	7 (9.5)	0 (0.0)		0.02*
Blood pressure at 12 months of therapy				0.068	Post-hoc
	Normal	56 (75.7)	60 (81.1)
	Controlled pretherapy hypertension	2 (2.7)	8 (10.8)		0.16
	Poorly controlled pretherapy hypertension	4 (5.4)	1 (1.4)		0.50
	New onset hypertension	9 (12.2)	3 (4.1)		0.20
Breakthrough bleeding		7 (9.5)	16 (21.6)	0.119
Thromboembolic disorders		1 (1.4)	0 (0.0)	0.541

Data are presented as number (percentage) or mean ± standard deviation.

LNG-IUS, levonorgestrel intrauterine system; MA, megestrol acetate.

*Statistically significant.